Skip to search formSkip to main contentSkip to account menu

lefradafiban

Known as: 5-((((4'-(imino(methoxycarbonyl)amino)methyl)(1,1'-biphenyl)-4-yl)oxy)methyl)-2-oxo-pyrrolidineacetic acid, methyl ester 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

Biphenyl CompoundsPyrrolidines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
Platelet Glycoprotein IIb / IIIa Receptor Inhibitors – Role in Coronary Artery Disease
Gp IIb/IIIa receptor antagonists are potent antiplatelet agents since they block the final pathway in platelet aggregation… 
2001
2001
Pharmacodynamics and safety of lefradafiban, an oral platelet glycoprotein IIb/IIIa receptor antagonist, in patients with stable coronary artery disease undergoing elective angioplasty
OBJECTIVE Lefradafiban is the orally active prodrug of fradafiban, a glycoprotein IIb/IIIa receptor antagonist. The present phase… 
2001
2001
Clinical trials with glycoprotein IIb/IIIa antagonists - No benefit without bleeding?
As the glycoprotein GPIIb/IIIa receptor is the final common pathway in platelet aggregation, antagonists of this receptor cause a… 
2000
2000
Absorption of lefradafiban from different sites of the gastrointestinal tract.
AIMS Fibrinogen receptor antagonists show a close relationship between plasma concentrations and inhibitory effect. Optimal… 
2000
2000
Safety and preliminary efficacy of one month glycoprotein IIb/IIIa inhibition with lefradafiban in patients with acute coronary syndromes without ST-elevation; a phase II study.
AIMS Oral glycoprotein IIb/IIIa inhibitors might enhance the early benefit of an intravenous agent and prevent subsequent cardiac… 
2000
2000
Lefradafiban is absorbed along the entire gastrointestinal tract,
  • 2000
  • Corpus ID: 195132466
1999
1999
Lefradafiban. BIBU 104, BIBU 104XX.
Review
1998
Review
1998
Platelet inhibition: new agents, new strategies, new trials
Review
1998
Review
1998
Glycoprotein IIb/IIIa receptor antagonists in the management of cardiovascular diseases.
Recent studies of the effects of glycoprotein (GP) IIb/IIIa receptor antagonists on the clinical outcomes of patients with… 
Highly Cited
1997
Highly Cited
1997
Profound and sustained inhibition of platelet aggregation by Fradafiban, a nonpeptide platelet glycoprotein IIb/IIIa antagonist, and its orally active prodrug, Lefradafiban, in men.
BACKGROUND Clinical trials have demonstrated that platelet glycoprotein (GP) IIb/IIIa antagonists effectively prevent acute… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)